(Q37857334)

24 August 2017

1 reference

title

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium (English)

1 reference

24 August 2017

0 references

1 reference

Bach-Yen T Nguyen

1

1 reference

24 August 2017

Robin D Isaacs

2

1 reference

24 August 2017

Hedy Teppler

3

1 reference

24 August 2017

Randi Y Leavitt

4

1 reference

24 August 2017

Peter Sklar

5

1 reference

24 August 2017

Marian Iwamoto

6

1 reference

24 August 2017

Larissa A Wenning

7

1 reference

24 August 2017

Michael D Miller

8

1 reference

24 August 2017

Joshua Chen

9

1 reference

24 August 2017

Ramon Kemp

10

1 reference

24 August 2017

Wei Xu

11

1 reference

24 August 2017

Robert A Fromtling

12

1 reference

24 August 2017

Joseph P Vacca

13

1 reference

24 August 2017

Steven D Young

14

1 reference

24 August 2017

Michael Rowley

15

1 reference

24 August 2017

Michael W Lower

16

1 reference

24 August 2017

Keith M Gottesdiener

17

1 reference

24 August 2017

Daria J Hazuda

18

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Annals of the New York Academy of Sciences

24 August 2017

1 reference

24 August 2017

1222

1 reference

24 August 2017

83-89

1 reference

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Retroviral intasome assembly and inhibition of DNA strand transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Lack of a significant drug interaction between raltegravir and tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05972.X

10.1111/J.1749-6632.2011.05972.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference